-
Mashup Score: 8At Chardan Conference, David Liu Foresees First Prime Editing Clinical Trial in 2024 - 7 month(s) ago
Genome editing pioneer David R. Liu, PhD, tells investors prime editing is on track to join base editing in human clinical trials in less than a year.
Source: www.genengnews.comCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0ASGCT News: David Liu Hails Rapid Progress in Precision Genome Editing - 11 month(s) ago
In an exemplary keynote address by David Liu, the developer of base and prime editing salutes the rapid uptake of “CRISPR 2.0” editing technologies around the world, as indicated by a succession of encouraging preclinical studies.
Categories: Future of Medicine, Latest HeadlinesTweet-
In an exemplary keynote address by @davidrliu, the developer of base and #primeediting salutes the rapid uptake of “#CRISPR 2.0” editing technologies around the world, as indicated by a succession of encouraging preclinical studies. Learn more: https://t.co/31gxSUnOG7 #ASGCT23 https://t.co/P1TA2eZOvf
-
-
Mashup Score: 1ASGCT News: David Liu Hails Rapid Progress in Precision Genome Editing - 11 month(s) ago
In an exemplary keynote address by David Liu, the developer of base and prime editing salutes the rapid uptake of “CRISPR 2.0” editing technologies around the world, as indicated by a succession of encouraging preclinical studies.
Categories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 1CRISPR-Based Prime Editing Generates Mouse Models of Cancer Mutations - 12 month(s) ago
Scientists make mice with the prime editing system engineered into their genome available for labs to carry out their own studies of cancer mutations.
Categories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 6CRISPR-Based Prime Editing Generates Mouse Models of Cancer Mutations - 12 month(s) ago
Scientists make mice with the prime editing system engineered into their genome available for labs to carry out their own studies of cancer mutations.
Categories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0Dual AAVs Enable In Vivo Prime Editing - 12 month(s) ago
A new Nature Biotechnology article from the lab of prime editor pioneer David Liu shows high-efficiency prime editing in vivo in mice.
Categories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0Dual AAVs Enable In Vivo Prime Editing - 12 month(s) ago
A new Nature Biotechnology article from the lab of prime editor pioneer David Liu shows high-efficiency prime editing in vivo in mice.
Categories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0Prime Editing Reverses Vision Loss in Mice - 1 year(s) ago
Prime editors, transduced using an AAV system, prevent photoreceptor degeneration and reverse vision loss in mice.
Categories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0Prime Editing Reverses Vision Loss in Mice - 1 year(s) ago
Prime editors, transduced using an AAV system, prevent photoreceptor degeneration and reverse vision loss in mice.
Categories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 1Search and Replace: Andrew Anzalone Details How Genome Editing Went Prime Time on “Close to the Edge” - 1 year(s) ago
Andrew Anzalone, MD, PhD, discusses his career in genome editing. He relates how he conceived the idea for prime editing, a “search and replace” gene editing approach, while he was a Jane Coffin Childs Memorial Fund postdoctoral fellow in the laboratory of David Liu, PhD.
Categories: Future of Medicine, Latest HeadlinesTweet-
Andrew Anzalone, MD, PhD, discusses his career in #genomeediting on Close to the Edge. He relates how he conceived the idea for #primeediting, while he was a Jane Coffin Childs Memorial Fund postdoctoral fellow in the laboratory of @davidrliu. Read more: https://t.co/cy5GX3nU9t https://t.co/t4nZPAIFkk
-
At Chardan Conference, David Liu Foresees First Prime Editing Clinical Trial in 2024 Genome editing pioneer David R. Liu, PhD, tells investors #primeediting is on track to join #baseediting in human clinical trials in less than a year. Learn more: https://t.co/19EzZdc7xd https://t.co/Ok4SXg2KVs